SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: ronrooster
Search This Board: 
Last Post: 5/18/2017 3:44:45 PM - Followers: 444 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Quarterly Report (10-q) 04/03/2017 02:19:18 PM
ENTB News: Quarterly Report (10-q) 01/11/2017 10:29:57 AM
#38100   yea gotinearly 05/18/17 03:44:45 PM
#38098   3rd try finally got some of those low salesleader 05/17/17 12:09:40 PM
#38097   Absolutely correct.In the mean time try to accumulate ronrooster 05/16/17 12:23:15 PM
#38096   When ready, it will be tested on animals jeffshir 05/16/17 12:18:50 PM
#38095   Great.Too bad PR did not mention ENTB/ZANDER. ronrooster 05/16/17 11:47:27 AM
#38094   Regen BioPharma, Inc. Sees Additional Positive Results on gotinearly 05/16/17 08:32:19 AM
#38093   Brother BM$N is moving from the trips, hope 72chevnj 05/12/17 02:51:19 PM
#38092   ENTB/ZANDER due for some REAL news soon.imo Raise ronrooster 05/08/17 04:00:02 PM
#38091   Couldn't agree more. I've even tried to MrBrakk 05/08/17 10:10:12 AM
#38090   No , I'm holding , didn't move quick salesleader 05/05/17 01:02:48 PM
#38089   No bad ENTB/ZANDER news that I can find.I ronrooster 05/05/17 12:20:12 PM
#38088   Did something happen ? bad news ? salesleader 05/05/17 12:10:23 PM
#38087   Lots of games being played with ENTB this ronrooster 04/28/17 10:33:14 AM
#38086   Just a group of day traders doing a SanDiegoAlan 04/27/17 01:21:15 AM
#38085   Holding mine for the cure! $$$$$$$$ 72chevnj 04/26/17 11:19:17 AM
#38084   With only approx.20 million float ,if ENTB can ronrooster 04/26/17 11:12:15 AM
#38083   Great news! Kbro13 04/26/17 09:39:45 AM
#38082   ENTB blowing up this morning gotinearly 04/26/17 09:36:49 AM
#38081   BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s BudFox1981 04/26/17 09:20:40 AM
#38080   Expect a quick spike at the bell$$$$$$$ Tha Part Time Er 04/26/17 09:10:12 AM
#38079   News out this morning! zigzagman 04/26/17 09:07:04 AM
#38078   ENTB HAS EMAIL ALERTS OUT! Traders keep an eye Cheers mrMando 04/26/17 06:43:52 AM
#38077   Lots of tweets today jeffshir 04/19/17 08:14:53 PM
#38076   progress is always good news jeffshir 04/19/17 03:48:15 PM
#38075   NEWS. Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates JokersWild12 04/19/17 10:11:43 AM
#38074   Market managers trying to drag Entb down -4 ronrooster 04/18/17 12:29:35 PM
#38073   Seems like big things are on the horizon 72chevnj 04/18/17 09:14:38 AM
#38072   Interesting acquisition by Zoetis demonstrates potential for ENTB_ZANDER> ronrooster 04/16/17 10:58:40 AM
#38071   NR2F6 NEWS.Regen BioPharma, Inc. Sees Success in Its ronrooster 04/12/17 02:51:44 PM
#38070   Not a big deal, however, ENTB float is ronrooster 04/09/17 01:38:21 PM
#38069   Just reviewing ENTB latest 10Q and thought the ronrooster 04/09/17 01:31:28 PM
#38068   ENTEST BIOMEDICAL INCORPORATED (OTCMKTS:ENTB) had a decrease of ronrooster 04/07/17 11:47:47 AM
#38067   Correct.with only 17 million float,any substantial PR will ronrooster 04/05/17 10:11:26 AM
#38066   I think with our float there is a salesleader 04/05/17 09:43:40 AM
#38065   Everyone is waiting.patience will pay off imo.gltu ronrooster 04/04/17 04:10:58 PM
#38064   hmmm, no buys or sales today, I guess salesleader 04/04/17 04:09:49 PM
#38063   I am of the opinion that it appears ronrooster 04/04/17 12:14:25 PM
#38062   The share structure relatively unchanged. Regarding no PR JokersWild12 04/04/17 12:06:50 PM
#38061   10Q outstanding shares 43,270,472.Hoping for news this week.glta ronrooster 04/03/17 02:43:29 PM
#38060   I think you are right about the optimization Watsonturtle 03/30/17 05:27:54 PM
#38059   Yes its odd that there has not been JokersWild12 03/30/17 01:27:43 PM
#38058   ENTB_ZANDER must be working on a HUGE DEAL, ronrooster 03/30/17 10:49:25 AM
#38057   You are right Joker, when she shows it salesleader 03/28/17 05:48:27 PM
#38056   $ENTB Kbro13 03/28/17 01:26:33 PM
#38055   Parris, is that really you? Welcome back. Can't JokersWild12 03/24/17 09:00:06 PM
#38054   ENTB BEEN A LOSER FOR TEN YEARS NOW parrishilton 03/24/17 04:55:07 PM
#38053   From the PR today at RGBP they are JokersWild12 03/23/17 05:47:33 PM
#38052   Fabulous News.Would have made sense to mention ENTB_ZANDER ronrooster 03/23/17 10:39:15 AM
#38051   Related NEWS: RGBP JokersWild12 03/23/17 10:24:21 AM
#38050   I guess ENTB_ZANDER is on the biweekly Thursday ronrooster 03/22/17 10:59:38 AM